Do analysts recommend IMAC or RDHL?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IMAC 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Redhill Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings & valuation, IMAC or RDHL?

Redhill Biopharma has lower revenue, but higher earnings than IMAC. IMAC is trading at a lower price-to-earnings ratio than Redhill Biopharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio IMAC $15.22M 0.09 -$10.54M -$0.27 N/A Redhill Biopharma $286K 17.88 -$430K $1.05 thousand 0.00

Does the media refer more to IMAC or RDHL?

In the previous week, IMAC had 1 more articles in the media than Redhill Biopharma. MarketBeat recorded 3 mentions for IMAC and 2 mentions for Redhill Biopharma. Redhill Biopharma's average media sentiment score of 0.94 beat IMAC's score of 0.17 indicating that Redhill Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IMAC 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Redhill Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate HCTI or IMAC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Healthcare Triangle 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 IMAC 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is HCTI or IMAC more profitable?

Healthcare Triangle has a net margin of -70.43% compared to IMAC's net margin of -75.40%. IMAC's return on equity of -52.17% beat Healthcare Triangle's return on equity. Company Net Margins Return on Equity Return on Assets Healthcare Triangle -70.43% -166.88% -43.00% IMAC -75.40% -52.17% -34.51%

Do analysts recommend IMAC or CAPS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IMAC 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Capstone Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is IMAC or CAPS more profitable?

Capstone Therapeutics has a net margin of -41.26% compared to IMAC's net margin of -75.40%. IMAC's return on equity of -52.17% beat Capstone Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets IMAC -75.40% -52.17% -34.51% Capstone Therapeutics -41.26% -114.15% -39.74%

Do analysts rate GELS or IMAC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gelteq 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 IMAC 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better valuation & earnings, GELS or IMAC?

Gelteq has higher earnings, but lower revenue than IMAC. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Gelteq $110K 43.91 -$4.30M N/A N/A IMAC $15.22M 0.09 -$10.54M -$0.27 N/A

Is GELS or IMAC more profitable?

Gelteq has a net margin of 0.00% compared to IMAC's net margin of -75.40%. Gelteq's return on equity of 0.00% beat IMAC's return on equity. Company Net Margins Return on Equity Return on Assets Gelteq N/A N/A N/A IMAC -75.40% -52.17% -34.51%

IMAC (IMAC) Competitors

$0.05 0.00 (0.00%)

As of 05/27/2026

Compare

IMAC vs. RDHL, HCTI, CAPS, EGRX, and GELS

Should you buy IMAC stock or one of its competitors? MarketBeat compares IMAC with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with IMAC include Redhill Biopharma (RDHL), Healthcare Triangle (HCTI), Capstone Therapeutics (CAPS), Eagle Pharmaceuticals (EGRX), and Gelteq (GELS). These companies are all part of the "medical" sector.

How does IMAC compare to Redhill Biopharma?

IMAC (NASDAQ:IMAC) and Redhill Biopharma (NASDAQ:RDHL) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, analyst recommendations, media sentiment, risk, dividends, profitability and institutional ownership.

IMAC has a beta of -0.88, suggesting that its share price is 188% less volatile than the broader market. Comparatively, Redhill Biopharma has a beta of 5.05, suggesting that its share price is 405% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IMAC	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Redhill Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Redhill Biopharma has lower revenue, but higher earnings than IMAC. IMAC is trading at a lower price-to-earnings ratio than Redhill Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IMAC	$15.22M	0.09	-$10.54M	-$0.27	N/A
Redhill Biopharma	$286K	17.88	-$430K	$1.05 thousand	0.00

Redhill Biopharma has a net margin of 0.00% compared to IMAC's net margin of -75.40%. Redhill Biopharma's return on equity of 0.00% beat IMAC's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IMAC	-75.40%	-52.17%	-34.51%
Redhill Biopharma	N/A	N/A	N/A

24.3% of IMAC shares are held by institutional investors. Comparatively, 7.2% of Redhill Biopharma shares are held by institutional investors. 10.0% of IMAC shares are held by insiders. Comparatively, 6.8% of Redhill Biopharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, IMAC had 1 more articles in the media than Redhill Biopharma. MarketBeat recorded 3 mentions for IMAC and 2 mentions for Redhill Biopharma. Redhill Biopharma's average media sentiment score of 0.94 beat IMAC's score of 0.17 indicating that Redhill Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IMAC	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Redhill Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Redhill Biopharma beats IMAC on 10 of the 14 factors compared between the two stocks.

How does IMAC compare to Healthcare Triangle?

Healthcare Triangle (NASDAQ:HCTI) and IMAC (NASDAQ:IMAC) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends.

Healthcare Triangle has a beta of 0.99, meaning that its stock price is 1% less volatile than the broader market. Comparatively, IMAC has a beta of -0.88, meaning that its stock price is 188% less volatile than the broader market.

Healthcare Triangle has a net margin of -70.43% compared to IMAC's net margin of -75.40%. IMAC's return on equity of -52.17% beat Healthcare Triangle's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Healthcare Triangle	-70.43%	-166.88%	-43.00%
IMAC	-75.40%	-52.17%	-34.51%

In the previous week, IMAC had 1 more articles in the media than Healthcare Triangle. MarketBeat recorded 3 mentions for IMAC and 2 mentions for Healthcare Triangle. Healthcare Triangle's average media sentiment score of 0.44 beat IMAC's score of 0.17 indicating that Healthcare Triangle is being referred to more favorably in the media.

Company	Overall Sentiment
Healthcare Triangle	Neutral
IMAC	Neutral

0.3% of Healthcare Triangle shares are held by institutional investors. Comparatively, 24.3% of IMAC shares are held by institutional investors. 0.1% of Healthcare Triangle shares are held by insiders. Comparatively, 10.0% of IMAC shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Healthcare Triangle has higher revenue and earnings than IMAC. IMAC is trading at a lower price-to-earnings ratio than Healthcare Triangle, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Healthcare Triangle	$20.04M	0.25	-$9.48M	-$66.69	N/A
IMAC	$15.22M	0.09	-$10.54M	-$0.27	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Healthcare Triangle	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
IMAC	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Healthcare Triangle beats IMAC on 8 of the 14 factors compared between the two stocks.

How does IMAC compare to Capstone Therapeutics?

IMAC (NASDAQ:IMAC) and Capstone Therapeutics (NASDAQ:CAPS) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, analyst recommendations, valuation, media sentiment, institutional ownership, risk, earnings and dividends.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IMAC	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Capstone Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

IMAC has higher earnings, but lower revenue than Capstone Therapeutics. IMAC is trading at a lower price-to-earnings ratio than Capstone Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IMAC	$15.22M	0.09	-$10.54M	-$0.27	N/A
Capstone Therapeutics	$48.11M	0.08	-$21.23M	-$3.37	N/A

IMAC has a beta of -0.88, suggesting that its stock price is 188% less volatile than the broader market. Comparatively, Capstone Therapeutics has a beta of -1.52, suggesting that its stock price is 252% less volatile than the broader market.

Capstone Therapeutics has a net margin of -41.26% compared to IMAC's net margin of -75.40%. IMAC's return on equity of -52.17% beat Capstone Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IMAC	-75.40%	-52.17%	-34.51%
Capstone Therapeutics	-41.26%	-114.15%	-39.74%

In the previous week, IMAC had 1 more articles in the media than Capstone Therapeutics. MarketBeat recorded 3 mentions for IMAC and 2 mentions for Capstone Therapeutics. Capstone Therapeutics' average media sentiment score of 0.96 beat IMAC's score of 0.17 indicating that Capstone Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
IMAC	Neutral
Capstone Therapeutics	Positive

24.3% of IMAC shares are held by institutional investors. Comparatively, 2.6% of Capstone Therapeutics shares are held by institutional investors. 10.0% of IMAC shares are held by insiders. Comparatively, 39.3% of Capstone Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

IMAC beats Capstone Therapeutics on 8 of the 14 factors compared between the two stocks.

How does IMAC compare to Eagle Pharmaceuticals?

IMAC (NASDAQ:IMAC) and Eagle Pharmaceuticals (NASDAQ:EGRX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, profitability, dividends, risk and media sentiment.

24.3% of IMAC shares are held by institutional investors. Comparatively, 85.4% of Eagle Pharmaceuticals shares are held by institutional investors. 10.0% of IMAC shares are held by insiders. Comparatively, 28.9% of Eagle Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, IMAC had 3 more articles in the media than Eagle Pharmaceuticals. MarketBeat recorded 3 mentions for IMAC and 0 mentions for Eagle Pharmaceuticals. IMAC's average media sentiment score of 0.17 beat Eagle Pharmaceuticals' score of 0.00 indicating that IMAC is being referred to more favorably in the media.

Company	Overall Sentiment
IMAC	Neutral
Eagle Pharmaceuticals	Neutral

Eagle Pharmaceuticals has a net margin of 0.00% compared to IMAC's net margin of -75.40%. Eagle Pharmaceuticals' return on equity of 0.00% beat IMAC's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IMAC	-75.40%	-52.17%	-34.51%
Eagle Pharmaceuticals	N/A	N/A	N/A

Eagle Pharmaceuticals has higher revenue and earnings than IMAC. IMAC is trading at a lower price-to-earnings ratio than Eagle Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IMAC	$15.22M	0.09	-$10.54M	-$0.27	N/A
Eagle Pharmaceuticals	$257.55M	0.03	$35.64M	$1.18	0.49

IMAC has a beta of -0.88, meaning that its share price is 188% less volatile than the broader market. Comparatively, Eagle Pharmaceuticals has a beta of 0.83, meaning that its share price is 17% less volatile than the broader market.

Summary

Eagle Pharmaceuticals beats IMAC on 10 of the 13 factors compared between the two stocks.

How does IMAC compare to Gelteq?

Gelteq (NASDAQ:GELS) and IMAC (NASDAQ:IMAC) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, valuation, media sentiment, analyst recommendations, profitability, institutional ownership and risk.

Gelteq has higher earnings, but lower revenue than IMAC.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gelteq	$110K	43.91	-$4.30M	N/A	N/A
IMAC	$15.22M	0.09	-$10.54M	-$0.27	N/A

In the previous week, IMAC had 1 more articles in the media than Gelteq. MarketBeat recorded 3 mentions for IMAC and 2 mentions for Gelteq. Gelteq's average media sentiment score of 0.44 beat IMAC's score of 0.17 indicating that Gelteq is being referred to more favorably in the media.

Company	Overall Sentiment
Gelteq	Neutral
IMAC	Neutral

Gelteq has a net margin of 0.00% compared to IMAC's net margin of -75.40%. Gelteq's return on equity of 0.00% beat IMAC's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gelteq	N/A	N/A	N/A
IMAC	-75.40%	-52.17%	-34.51%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gelteq	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
IMAC	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

24.3% of IMAC shares are owned by institutional investors. 10.0% of IMAC shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Gelteq has a beta of 0.06, suggesting that its stock price is 94% less volatile than the broader market. Comparatively, IMAC has a beta of -0.88, suggesting that its stock price is 188% less volatile than the broader market.

Summary

Gelteq beats IMAC on 8 of the 12 factors compared between the two stocks.

Get IMAC News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IMAC vs. The Competition

Export

Metric	IMAC	Specialty Outpatient Clinics Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.32M	$1.06M	$6.43B	$12.58B
Dividend Yield	N/A	N/A	2.75%	5.25%
P/E Ratio	-0.19	N/A	21.48	26.18
Price / Sales	0.09	0.09	582.03	104.40
Price / Cash	N/A	N/A	43.13	56.80
Price / Book	0.07	0.07	10.52	7.24
Net Income	-$10.54M	-$10.54M	$3.56B	$337.24M
7 Day Performance	N/A	N/A	3.02%	3.77%
1 Month Performance	N/A	N/A	4.43%	5.72%
1 Year Performance	N/A	N/A	37.64%	38.49%

IMAC Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IMAC IMAC	N/A	$0.05 flat	N/A	+51.5%	$1.32M	$15.22M	N/A	106
RDHL Redhill Biopharma	1.1372 of 5 stars	$0.94 +1.7%	N/A	-45.1%	$4.85M	$290K	0.00	210
HCTI Healthcare Triangle	0.3899 of 5 stars	$2.37 flat	N/A	-97.3%	$4.81M	$13.89M	N/A	80	Short Interest Increase
CAPS Capstone Therapeutics	1.021 of 5 stars	$0.33 -14.0%	N/A	-83.3%	$4.78M	$48.11M	N/A	38	Short Interest Decrease Gap Down
EGRX Eagle Pharmaceuticals	N/A	$0.37 -2.7%	N/A	-70.5%	$4.74M	$257.55M	0.31	100	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IMAC) was last updated on 5/28/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

IMAC (IMAC) Competitors

IMAC vs. RDHL, HCTI, CAPS, EGRX, and GELS

How does IMAC compare to Redhill Biopharma?

Summary

How does IMAC compare to Healthcare Triangle?

Summary

How does IMAC compare to Capstone Therapeutics?

Summary

How does IMAC compare to Eagle Pharmaceuticals?

Summary

How does IMAC compare to Gelteq?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMAC vs. The Competition

IMAC Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

IMAC (IMAC) Competitors

IMAC vs. RDHL, HCTI, CAPS, EGRX, and GELS

How does IMAC compare to Redhill Biopharma?

Which has more risk and volatility, IMAC or RDHL?

Do analysts recommend IMAC or RDHL?

Which has preferable earnings & valuation, IMAC or RDHL?

Is IMAC or RDHL more profitable?

Do institutionals and insiders have more ownership in IMAC or RDHL?

Does the media refer more to IMAC or RDHL?

Summary

How does IMAC compare to Healthcare Triangle?

Which has more volatility & risk, HCTI or IMAC?

Is HCTI or IMAC more profitable?

Does the media favor HCTI or IMAC?

Do insiders and institutionals hold more shares of HCTI or IMAC?

Which has higher earnings & valuation, HCTI or IMAC?

Do analysts rate HCTI or IMAC?

Summary

How does IMAC compare to Capstone Therapeutics?

Do analysts recommend IMAC or CAPS?

Which has stronger earnings & valuation, IMAC or CAPS?

Which has more volatility and risk, IMAC or CAPS?

Is IMAC or CAPS more profitable?

Does the media refer more to IMAC or CAPS?

Do institutionals and insiders have more ownership in IMAC or CAPS?

Summary

How does IMAC compare to Eagle Pharmaceuticals?

Do institutionals and insiders have more ownership in IMAC or EGRX?

Does the media refer more to IMAC or EGRX?

Is IMAC or EGRX more profitable?

Which has better earnings & valuation, IMAC or EGRX?

Which has more risk & volatility, IMAC or EGRX?

Summary

How does IMAC compare to Gelteq?

Which has better valuation & earnings, GELS or IMAC?

Does the media prefer GELS or IMAC?

Is GELS or IMAC more profitable?

Do analysts rate GELS or IMAC?

Do institutionals and insiders hold more shares of GELS or IMAC?

Which has more volatility & risk, GELS or IMAC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMAC vs. The Competition

IMAC Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools